May 2010
Reactions Weekly;5/22/2010, Issue 1302, p13
Case Study
The article presents the case of four elderly patients who developed ocular hypertension following intravitreal injections of bevacizumab or rabinizumab for choroidal neovascular membrane (CNVM) secondary to age-related macular degeneration (AMD)


Related Articles

  • Bevacizumab.  // Reactions Weekly;12/4/2010, Issue 1330, p11 

    The article describes the case of a 38-year-old man, diagnosed with right vestibular schwannoma (VS), who developed hypertension after receiving an infusion of bevacizumab.

  • Bevacizumab.  // Reactions Weekly;11/2/2013, Issue 1476, p9 

    The article presents case studies of three women who developed oesophagitis, ventricular extrasystoles and arterial hypertension after taking bevacizumab for nonmetastatic breast cancer (BC).

  • Bevacizumab.  // Reactions Weekly;Feb2015, Vol. 1537 Issue 1, p55 

    The article presents case studies of three elderly male patients who developed resistant hypertension while receiving chemotherapy with bevacizumab.

  • Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. Bear, Harry D.; Tang, Gong; Rastogi, Priya; Geyer, Charles E.; Robidoux, Andr´┐Ż; Atkins, James N.; Baez-Diaz, Luis; Brufsky, Adam M.; Mehta, Rita S.; Fehrenbacher, Louis; Young, James A.; Senecal, Francis M.; Gaur, Rakesh; Margolese, Richard G.; Adams, Paul T.; Gross, Howard M.; Costantino, Joseph P.; Swain, Sandra M.; Mamounas, Eleftherios P.; Wolmark, Norman // New England Journal of Medicine;1/26/2012, Vol. 366 Issue 4, p310 

    Background: Bevacizumab and the antimetabolites capecitabine and gemcitabine have been shown to improve outcomes when added to taxanes in patients with metastatic breast cancer. The primary aims of this trial were to determine whether the addition of capecitabine or gemcitabine to neoadjuvant...

  • Bevacizumab-induced hypertension may predict outcomes for CRC.  // Hem/Onc Today;11/25/2008, Vol. 9 Issue 21, p24 

    This article focuses on a study which examined bevacizumab-induced hypertension as a prognostic factor for outcome in patients with colorectal cancer. The study involves 39 patients receiving first-line bevacizumab combined with irinotecan and 5-FU. An overview of the study methodology and key...

  • Bevacizumab.  // Reactions Weekly;5/9/2009, Issue 1251, p9 

    The article presents a case report involving an elderly Japanese patient with hypertension. The case report serves as a case of therapy for bevacizumab-induced hypertension.

  • Bevacizumab.  // Reactions Weekly;11/29/2008, Issue 1230, p9 

    The article describes the case of a 70-year-old man who experienced a worsening hypertension followed by acute aortic dissection upon receiving bevacizumab as part of a clinical trial investigating metastatic prostate cancer. After 10 months of taking bevacizumab 15 milligrams (mg)/kilogram (kg)...

  • Bevacizumab.  // Reactions Weekly;11/7/2009, Issue 1277, p10 

    The article describes the clinical cases of two patients who developed epistaxis and one patient who developed hypertension while under bevacizumab treatment regimen. All patients were diagnosed with bronchogenic adenocarcinoma. Their medical histories are described. The patients who developed...

  • Bevacizumab.  // Reactions Weekly;03/01/2013, Issue 1441, p11 

    A 69-year-old woman developed hypertension and proteinuria while receiving bevacizumab for lung adenocarcinoma.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics